跳至主要内容
临床试验/NCT00145457
NCT00145457已完成4 期

A Multicentre Study on the Capacity of the IGF-1 Stimulation Test to Predict the Growth Promoting Effect of Standard and High Doses of Genotonorm® in Prepubertal Children With Growth Hormone Deficiency.

Pfizer9 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2001年4月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
Pfizer
入组人数
82
试验地点
9
主要终点
Change of height standard deviation score after 24 months of treatment according to the short term response of plasma IGF1 to Genotonorm.

研究概览

简要总结

To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
4 Years 至 11 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male or female aged of more than 4 years.
  • GHD defined as a peak GH level < 20 mUI/ml at two different pharmacological GH provocative tests including one done with two pharmacological agents and both performed within the year before the inclusion, according to the current recommendations of the French Health Authorities

排除标准

  • Previous treatment with GH
  • Ongoing pharmacological treatment with steroids except if corresponding to substitutive therapy

结局指标

主要结局

Change of height standard deviation score after 24 months of treatment according to the short term response of plasma IGF1 to Genotonorm.

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (9)

Loading locations...

相似试验